10 June 2014 - Deborah Wilkes
Archived
Allergan has rejected a revised offer from Pershing Square Capital Management and Valeant Pharmaceuticals International that values the Botox maker at around US$53 billion.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.